POLYMED

Poly Medicure Share Price

₹2,221.70 +19.95 (0.91%)

22 Feb, 2025 21:40

SIP TrendupStart SIP in POLYMED

Start SIP

Performance

  • Low
  • ₹2,155
  • High
  • ₹2,231
  • 52 Week Low
  • ₹1,373
  • 52 Week High
  • ₹3,358
  • Open Price₹2,202
  • Previous Close₹2,202
  • Volume126,979

Investment Returns

  • Over 1 Month -11.82%
  • Over 3 Month -14.19%
  • Over 6 Month + 1.77%
  • Over 1 Year + 37.7%
SIP Lightning

Smart Investing Starts Here Start SIP with Poly Medicure for Steady Growth!

Invest Now

Poly Medicure Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 71.4
  • PEG Ratio
  • 2.7
  • Market Cap Cr
  • 22,512
  • P/B Ratio
  • 8.7
  • Average True Range
  • 127.22
  • EPS
  • 31.1
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -89.8
  • RSI
  • 41.83
  • MFI
  • 51.14

Poly Medicure Financials

Poly Medicure Technicals

EMA & SMA

Current Price
₹2,221.70
+ 19.95 (0.91%)
pointer
  • stock-down_img
  • Bearish Moving Average 12
  • stock-up_img
  • Bullish Moving Average 4
  • 20 Day
  • ₹2,285.28
  • 50 Day
  • ₹2,421.28
  • 100 Day
  • ₹2,447.73
  • 200 Day
  • ₹2,294.36

Resistance and Support

2202.77 Pivot Speed
  • R3 2,326.08
  • R2 2,278.67
  • R1 2,250.18
  • S1 2,174.28
  • S2 2,126.87
  • S3 2,098.38

What's your outlook on Poly Medicure?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Poly Medicure Ltd. is a leading Indian manufacturer of medical devices, specializing in infusion therapy, dialysis, urology, and diagnostics. With 8 global manufacturing facilities, it delivers high-quality healthcare products to patients and healthcare providers worldwide.

Poly Medicure has an operating revenue of Rs. 1,607.08 Cr. on a trailing 12-month basis. An annual revenue growth of 25% is outstanding, Pre-tax margin of 25% is great, ROE of 17% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 88 which is a GOOD score indicating consistency in earnings, a RS Rating of 73 which is FAIR indicating the recent price performance, Buyer Demand at E which indicates heavy supply, Group Rank of 54 indicates it belongs to a fair industry group of Medical-Systems/Equip and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Poly Medicure Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-03 Quarterly Results & Others To consider other business matters. per share(40%)Interim Dividend
2024-10-28 Quarterly Results & ESOP
2024-07-22 Quarterly Results
2024-06-29 Others Inter alia, to consider and finalize the terms and condition and approve the modes of fund raising. per share(40%)Interim Dividend
2024-05-17 Audited Results & Final Dividend

Poly Medicure F&O

Poly Medicure Shareholding Pattern

62.44%
7.17%
2.44%
12.33%
10.55%
5.07%

About Poly Medicure

  • NSE Symbol
  • POLYMED
  • BSE Symbol
  • 531768
  • Managing Director
  • Mr. Himanshu Baid
  • ISIN
  • INE205C01021

Similar Stocks to Poly Medicure

Poly Medicure FAQs

Poly Medicure share price is ₹2,221 As on 22 February, 2025 | 21:26

The Market Cap of Poly Medicure is ₹22511.5 Cr As on 22 February, 2025 | 21:26

The P/E ratio of Poly Medicure is 71.4 As on 22 February, 2025 | 21:26

The PB ratio of Poly Medicure is 8.7 As on 22 February, 2025 | 21:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23